# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances
131, Journal, 0, 16, "Horm Metab Res .", "", "<http://ctro/data#Publication_48712> <http://ctro/data#hasJournal> \"Horm Metab Res .\"."
0, PublicationYear, 17, 21, "2007", "", "<http://ctro/data#Publication_48712> <http://ctro/data#hasPublicationYear> \"2007\"."
68, Title, 50, 217, "Improved meal - related insulin processing contributes to the enhancement of B - cell function by the DPP - 4 inhibitor vildagliptin in patients with type 2 diabetes .", "", "<http://ctro/data#Publication_48712> <http://ctro/data#hasTitle> \"Improved meal - related insulin processing contributes to the enhancement of B - cell function by the DPP - 4 inhibitor vildagliptin in patients with type 2 diabetes .\"."
1, Insulin, 74, 81, "insulin", "", 
2, Vildagliptin, 170, 182, "vildagliptin", "", 
3, Type2Diabetes, 200, 215, "type 2 diabetes", "", 
4, Author, 218, 227, "Ahr é n B", "", "<http://ctro/data#Publication_48712> <http://ctro/data#hasAuthor> \"Ahr é n B\"."
5, Author, 236, 244, "Pacini G", "", "<http://ctro/data#Publication_48712> <http://ctro/data#hasAuthor> \"Pacini G\"."
6, Author, 247, 253, "Tura A", "", "<http://ctro/data#Publication_48712> <http://ctro/data#hasAuthor> \"Tura A\"."
7, Author, 256, 264, "Foley JE", "", "<http://ctro/data#Publication_48712> <http://ctro/data#hasAuthor> \"Foley JE\"."
8, Author, 267, 278, "Schweizer A", "", "<http://ctro/data#Publication_48712> <http://ctro/data#hasAuthor> \"Schweizer A\"."
9, Sweden, 390, 396, "Sweden", "", "<http://ctro/data#Population_48739> <http://ctro/data#hasCountry> <http://ctro/data#Sweden>."
97, ObjectiveDescription, 426, 610, "The aim of this study was to evaluate the contribution of insulin processing to the improved meal - related B - cell function previously shown with the DPP - 4 inhibitor vildagliptin .", "", "<http://ctro/data#ClinicalTrial_48723> <http://ctro/data#hasObjectiveDescription> \"The aim of this study was to evaluate the contribution of insulin processing to the improved meal - related B - cell function previously shown with the DPP - 4 inhibitor vildagliptin .\"."
10, Insulin, 484, 491, "insulin", "", 
11, Vildagliptin, 596, 608, "vildagliptin", "", 
12, NumberPatientsCT, 611, 623, "Fifty - five", "", "<http://ctro/data#ClinicalTrial_48723> <http://ctro/data#hasNumberPatientsCT> \"Fifty - five\"."
106299, Precondition, 624, 746, "patients with type 2 diabetes ( 56 . 5 + / - 1 . 5 years ; BMI = 29 . 6 + / - 0 . 5 kg / m ( 2 ) ; FPG = 9 . 9 + / - 0 . 2", "", "<http://ctro/data#Population_48739> <http://ctro/data#hasPrecondition> \"patients with type 2 diabetes ( 56 . 5 + / - 1 . 5 years ; BMI = 29 . 6 + / - 0 . 5 kg / m ( 2 ) ; FPG = 9 . 9 + / - 0 . 2\". <http://ctro/data#Population_48739> <http://ctro/data#hasPrecondition> \"mmol / l ; HbA1c = 7 . 7 + / - 0 . 1 % ) were studied : 29 patients were treated with vildagliptin and 26 patients with placebo , both added to an ongoing metformin regimen ( 1 . 5 - 3 . 0 g / day ) .\"."
13, Type2Diabetes, 638, 653, "type 2 diabetes", "", "<http://ctro/data#ClinicalTrial_48723> <http://ctro/data#analysesHealthCondition> <http://ctro/data#Type2Diabetes>."
14, AvgAge, 656, 662, "56 . 5", "", "<http://ctro/data#Population_48739> <http://ctro/data#hasAvgAge> \"56 . 5\"."
87, Year, 675, 680, "years", "", 
15, BMI, 683, 686, "BMI", "", 
85, BaseLineValue, 689, 695, "29 . 6", "", 
50307, SdDevBL, 702, 707, "0 . 5", "", 
16, Kg_per_squareMeter, 708, 720, "kg / m ( 2 )", "", 
17, FastingPlasmaGlucose, 723, 726, "FPG", "", 
86, BaseLineValue, 729, 734, "9 . 9", "", 
50308, SdDevBL, 741, 746, "0 . 2", "", 
18, Millimoles_per_litre, 747, 755, "mmol / l", "", 
106299, Precondition, 747, 947, "mmol / l ; HbA1c = 7 . 7 + / - 0 . 1 % ) were studied : 29 patients were treated with vildagliptin and 26 patients with placebo , both added to an ongoing metformin regimen ( 1 . 5 - 3 . 0 g / day ) .", "", 
19, HbA1c, 758, 763, "HbA1c", "", 
84, BaseLineValue, 766, 771, "7 . 7", "", 
50309, SdDevBL, 778, 783, "0 . 1", "", 
20, Percentage, 784, 785, "%", "", 
21, NumberPatientsArm, 803, 805, "29", "", "<http://ctro/data#Arm_48782> <http://ctro/data#hasNumberPatientsArm> \"29\"."
22, Vildagliptin, 833, 845, "vildagliptin", "", "<http://ctro/data#Medication_48893> <http://ctro/data#hasDrug> <http://ctro/data#Vildagliptin>."
23, NumberPatientsArm, 850, 852, "26", "", "<http://ctro/data#Arm_48791> <http://ctro/data#hasNumberPatientsArm> \"26\"."
24, Placebo, 867, 874, "placebo", "", "<http://ctro/data#Medication_48900> <http://ctro/data#hasDrug> <http://ctro/data#Placebo>."
25, Metformin, 902, 911, "metformin", "", 
26, DoseValue, 922, 935, "1 . 5 - 3 . 0", "", 
27, Gram, 936, 937, "g", "", 
28, Interval, 940, 943, "day", "", "<http://ctro/data#Intervention_48881> <http://ctro/data#hasInterval> \"day\". <http://ctro/data#Intervention_91757> <http://ctro/data#hasInterval> \"day\"."
134, TimePoint, 986, 994, "baseline", "", 
30, Duration, 1005, 1013, "52 weeks", "", "<http://ctro/data#ClinicalTrial_48723> <http://ctro/data#hasCTduration> \"52 weeks\"."
32, Insulin, 1033, 1043, "proinsulin", "", 
50310, EndPointDescription, 1055, 1072, "insulin secretion", "", 
35, EndPointDescription, 1179, 1196, "B - cell function", "", 
37, Vildagliptin, 1236, 1248, "vildagliptin", "", 
38, Placebo, 1251, 1258, "placebo", "", 
101, Mean, 1264, 1268, "mean", "", 
139, TimePoint, 1281, 1289, "baseline", "", 
50311, EndPointDescription, 1293, 1332, "fasting proinsulin to C - peptide ratio", "", "<http://ctro/data#EndPointDescription_48768> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_48767> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_48768>."
50312, EndPointDescription, 1335, 1344, "fastP / C", "", 
103, DiffGroupAbsValue, 1351, 1360, "- 0 . 007", "", "<http://ctro/data#DiffBetweenGroups_48968> <http://ctro/data#hasDiffGroupAbsValue> \"- 0 . 007\"."
44, SdDevDiff, 1367, 1374, "0 . 009", "", "<http://ctro/data#DiffBetweenGroups_48968> <http://ctro/data#hasStandardDevDiff> \"0 . 009\"."
45, PvalueDiff, 1377, 1388, "p = 0 . 052", "", "<http://ctro/data#DiffBetweenGroups_48968> <http://ctro/data#hasPvalueDiff> \"p = 0 . 052\"."
46, Duration, 1428, 1436, "52 weeks", "", 
47, Vildagliptin, 1455, 1467, "vildagliptin", "", 
41, EndPointDescription, 1496, 1535, "dynamic proinsulin to C - peptide ratio", "", "<http://ctro/data#EndPointDescription_48773> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_48772> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_48773>."
42, EndPointDescription, 1538, 1546, "dynP / C", "", 
48, Placebo, 1561, 1568, "placebo", "", 
50313, Reduction, 1572, 1579, "0 . 010", "", "<http://ctro/data#Outcome_48977> <http://ctro/data#hasChangeValue> \"0 . 010\"."
50314, SdDevChangeValue, 1586, 1593, "0 . 008", "", "<http://ctro/data#Outcome_48977> <http://ctro/data#hasSdDevChangeValue> \"0 . 008\"."
51, PValueChangeValue, 1596, 1607, "p = 0 . 037", "", "<http://ctro/data#Outcome_48977> <http://ctro/data#hasPValueChangeValue> \"p = 0 . 037\"."
52, EndPointDescription, 1635, 1640, "P / C", "", "<http://ctro/data#EndPointDescription_48778> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_48777> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_48778>."
54, FastingPlasmaGlucose, 1707, 1722, "fasting glucose", "", 
55, EndPointDescription, 1727, 1738, "glucose AUC", "", 
53, EndPointDescription, 1778, 1783, "P / C", "", "<http://ctro/data#EndPointDescription_48778> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_48777> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_48778>."
118, ObservedResult, 1804, 1829, "was significantly reduced", "", "<http://ctro/data#Outcome_49004> <http://ctro/data#hasObservedResult> \"was significantly reduced\"."
56, Vildagliptin, 1835, 1847, "vildagliptin", "", 
57, Placebo, 1853, 1860, "placebo", "", 
50315, ObservedResult, 1863, 1939, "both in the fasting state ( p = 0 . 023 ) and postprandially ( p = 0 . 004 )", "", "<http://ctro/data#Outcome_49004> <http://ctro/data#hasObservedResult> \"both in the fasting state ( p = 0 . 023 ) and postprandially ( p = 0 . 004 )\"."
59, PvalueDiff, 1891, 1902, "p = 0 . 023", "", "<http://ctro/data#DiffBetweenGroups_49059> <http://ctro/data#hasPvalueDiff> \"p = 0 . 023\"."
60, PvalueDiff, 1926, 1937, "p = 0 . 004", "", "<http://ctro/data#DiffBetweenGroups_49068> <http://ctro/data#hasPvalueDiff> \"p = 0 . 004\"."
121, ConclusionComment, 1942, 2130, "In conclusion , a more efficient B - cell insulin processing provides further evidence that vildagliptin treatment ameliorates abnormal B - cell function in patients with type 2 diabetes .", "", "<http://ctro/data#ClinicalTrial_48723> <http://ctro/data#hasConclusionComment> \"In conclusion , a more efficient B - cell insulin processing provides further evidence that vildagliptin treatment ameliorates abnormal B - cell function in patients with type 2 diabetes .\"."
61, Insulin, 1984, 1991, "insulin", "", 
62, Vildagliptin, 2034, 2046, "vildagliptin", "", 
63, Type2Diabetes, 2113, 2128, "type 2 diabetes", "", 
64, PMID, 2174, 2182, "17992639", "", "<http://ctro/data#Publication_48712> <http://ctro/data#hasPMID> \"17992639\"."
